<p>Liquidia（纳斯达克代码：LQDA - 获取免费报告）的股票在周五发布给投资者的报告中，BTIG Research 的分析师重申了其 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价为 49.00 美元。BTIG Research 的目标价暗示该公司股价有 38.11% 的潜在上涨空间。</p>
<ul>
<li>MarketBeat 周回顾：12/25 - 12/29</li>
</ul>
<p>其他几家券商也对 LQDA 发布了报告。华尔街 Zen 在 12 月 6 日的研究报告中将 Liquidia 的评级从 “买入” 下调至 “持有”。雷蒙德·詹姆斯金融在 11 月 4 日的研究报告中重申了 “强力买入” 评级，并将 Liquidia 的目标价设定为 47.00 美元。杰富瑞金融集团在 11 月 3 日的研究报告中重申了 “买入” 评级，并对 Liquidia 的目标价设定为 45.00 美元。富国银行在 10 月 20 日的研究报告中开始覆盖 Liquidia 的股票，设定了 “增持” 评级和 31.00 美元的目标价。最后，Needham &amp; Company LLC 在 11 月 4 日的研究报告中将 Liquidia 的目标价从 36.00 美元上调至 52.00 美元，并给予该公司 “买入” 评级。一位分析师给予该股票 “强力买入” 评级，七位分析师给予 “买入” 评级，二位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Liquidia 目前的平均评级为 “适度买入”，平均目标价为 38.56 美元。</p>
<p><strong>获取我们对 Liquidia 的最新分析</strong></p>
<h2>Liquidia 股票表现</h2>
<ul>
<li>Liquidia：法院胜利是行业巨头的觉醒？</li>
</ul>
<p>在周五的午盘交易中，纳斯达克 LQDA 的股票下跌 0.31 美元，达到 35.48 美元。该公司交易了 163,492 股，较其平均交易量 1,941,798 股有所减少。该公司的市值为 30.9 亿美元，市盈率为-24.64，贝塔值为 0.48。公司流动比率为 1.96，当前比率为 2.20，债务股本比率为 6.19。Liquidia 的 12 个月低点为 11.26 美元，12 个月高点为 36.41 美元。公司的 50 日简单移动平均线为 29.46 美元，200 日简单移动平均线为 23.63 美元。</p>
<p>Liquidia（纳斯达克代码：LQDA - 获取免费报告）最近在 11 月 3 日发布了季度财报。公司报告每股收益（EPS）为-0.04 美元，超出市场共识预期的-0.45 美元，超出幅度为 0.41 美元。Liquidia 的净利润率为-176.04%，股本回报率为-296.78%。该季度的营业收入为 5434 万美元，而分析师预期为 1886 万美元。与去年同期相比，该季度的营业收入增长了 1106.7%。整体来看，研究分析师预测 Liquidia 在本年度的每股收益将为-1.51 美元。</p>
<h2>内部活动</h2>
<p>在其他新闻中，内部人士 Rajeev Saggar 在 11 月 5 日的交易中出售了 71,381 股公司的股票，交易均价为 27.00 美元，总交易额为 1,927,287.00 美元。交易后，该内部人士直接持有 176,549 股公司股票，价值约为 4,766,823 美元。这笔交易代表其持股比例减少了 28.79%。该交易已在 SEC 的法律文件中披露，相关文件可通过此链接访问。此外，公司的总法律顾问 Russell Schundler 在 12 月 1 日的交易中出售了 1,072 股公司的股票，交易均价为 32.19 美元，总价值为 34,507.68 美元。交易完成后，总法律顾问直接持有 577,288 股公司股票，价值约为 18,582,900.72 美元。该交易使其持股比例减少了 0.19%。该销售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士共出售了价值 4,500,450 美元的 169,644 股公司股票。公司内部人士持有公司 26.50% 的股份。</p>
<h2>机构投资者对 Liquidia 的看法</h2>
<p>对冲基金最近对该公司的持仓进行了调整。Farallon Capital Management LLC 在第三季度将其在 Liquidia 的持仓增加了 102.1%。Farallon Capital Management LLC 目前持有 8565638 股公司股票，价值 194,783,000 美元，此前在上个季度又增持了 4,326,876 股。TCG Crossover Management LLC 在第三季度购买了 Liquidia 的新股份，价值 38,887,000 美元。Caprock Group LLC 在第三季度购买了 Liquidia 的新股份，价值 37,114,000 美元。Tyro Capital Management LLC 在第二季度收购了 Liquidia 的新股份，价值 15,473,000 美元。最后，CenterBook Partners LP 在第二季度将其在 Liquidia 的持仓增加了 811.7%。CenterBook Partners LP 目前持有 1103850 股公司股票，价值 13,754,000 美元，此前在上个季度又增持了 982,778 股。机构投资者和对冲基金持有公司 64.54% 的股份。</p>
<h2>Liquidia 公司简介</h2>
<p>（获取免费报告）</p>
<p>Liquidia Technologies, Inc 是一家临床阶段的生物制药公司，总部位于北卡罗来纳州的研究三角园区。该公司利用其专有的 PRINT®（非湿润模板中的颗粒复制）平台来工程化精确形状和大小的药物颗粒，旨在改善药物的递送、疗效和安全性。通过控制纳米尺度的颗粒特性，Liquidia 旨在增强依赖于靶向递送的呼吸和其他疗法。</p>
<p>该公司的主要产品候选药物 LIQ861 是一种用于吸入的干粉制剂，适用于患有肺动脉高压（PAH）的患者。</p>
<h2>特色故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Liquidia</li>
<li>NNVC 在 2026 年可能会颠覆生物科技领域，估值为 7 美元</li>
<li>BNZI 发布创纪录的第三季度收入 – 看看是什么推动了这一增长。</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>[如何] 认领你在 SpaceX 的 IPO 前股份！</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFFEQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFFEQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Liquidia 吗？</h2>
<p>在你考虑 Liquidia 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Liquidia 并不在名单上。</p>
<p>虽然 Liquidia 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LQDA

<p>BTIG Research 重申了对 Liquidia（NASDAQ:LQDA）的 “买入” 评级，目标价为 49.00 美元，暗示有 38.11% 的上涨空间。其他分析师的评级则各有不同，平均评级为 “适度买入”，目标价为 38.56 美元。Liquidia 的股票表现显示市值为 30.9 亿美元，并且最近有内部交易活动。机构投资者增加了他们的持仓，对冲基金也获得了显著的股份</p>

<p>Liquidia (NASDAQ:LQDA - Get Free Report)'s stock had its &#34;buy&#34; rating restated by analysts at BTIG Research in a note issued to investors on Friday,Benzinga reports. They currently have a $49.00 price target on the stock. BTIG Research's price target would suggest a potential upside of 38.11% from the company's previous close.</p>
<div class="lb-trans"><p>Liquidia（纳斯达克代码：LQDA - 获取免费报告）的股票在周五发布给投资者的报告中，BTIG Research 的分析师重申了其 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价为 49.00 美元。BTIG Research 的目标价暗示该公司股价有 38.11% 的潜在上涨空间。</p>
</div><ul>
<li>MarketBeat Week in Review: 12/25 - 12/29</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾：12/25 - 12/29</li>
</ul>
</div><p>Several other brokerages have also issued reports on LQDA. Wall Street Zen lowered Liquidia from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, December 6th. Raymond James Financial reissued a &#34;strong-buy&#34; rating and set a $47.00 target price on shares of Liquidia in a research note on Tuesday, November 4th. Jefferies Financial Group reaffirmed a &#34;buy&#34; rating and issued a $45.00 price target on shares of Liquidia in a research note on Monday, November 3rd. Wells Fargo &amp; Company began coverage on shares of Liquidia in a research report on Monday, October 20th. They set an &#34;overweight&#34; rating and a $31.00 price objective on the stock. Finally, Needham &amp; Company LLC boosted their target price on Liquidia from $36.00 to $52.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, Liquidia currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $38.56.</p>
<div class="lb-trans"><p>其他几家券商也对 LQDA 发布了报告。华尔街 Zen 在 12 月 6 日的研究报告中将 Liquidia 的评级从 “买入” 下调至 “持有”。雷蒙德·詹姆斯金融在 11 月 4 日的研究报告中重申了 “强力买入” 评级，并将 Liquidia 的目标价设定为 47.00 美元。杰富瑞金融集团在 11 月 3 日的研究报告中重申了 “买入” 评级，并对 Liquidia 的目标价设定为 45.00 美元。富国银行在 10 月 20 日的研究报告中开始覆盖 Liquidia 的股票，设定了 “增持” 评级和 31.00 美元的目标价。最后，Needham &amp; Company LLC 在 11 月 4 日的研究报告中将 Liquidia 的目标价从 36.00 美元上调至 52.00 美元，并给予该公司 “买入” 评级。一位分析师给予该股票 “强力买入” 评级，七位分析师给予 “买入” 评级，二位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Liquidia 目前的平均评级为 “适度买入”，平均目标价为 38.56 美元。</p>
</div><p><strong>Get Our Latest Analysis on Liquidia</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Liquidia 的最新分析</strong></p>
</div><h2>Liquidia Stock Performance</h2>
<div class="lb-trans"><h2>Liquidia 股票表现</h2>
</div><ul>
<li>Liquidia: Court victory the awakening of an industry giant?</li>
</ul>
<div class="lb-trans"><ul>
<li>Liquidia：法院胜利是行业巨头的觉醒？</li>
</ul>
</div><p>Shares of NASDAQ LQDA traded down $0.31 during mid-day trading on Friday, reaching $35.48. 163,492 shares of the company were exchanged, compared to its average volume of 1,941,798. The stock has a market capitalization of $3.09 billion, a P/E ratio of -24.64 and a beta of 0.48. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. Liquidia has a twelve month low of $11.26 and a twelve month high of $36.41. The company's 50-day simple moving average is $29.46 and its 200-day simple moving average is $23.63.</p>
<div class="lb-trans"><p>在周五的午盘交易中，纳斯达克 LQDA 的股票下跌 0.31 美元，达到 35.48 美元。该公司交易了 163,492 股，较其平均交易量 1,941,798 股有所减少。该公司的市值为 30.9 亿美元，市盈率为-24.64，贝塔值为 0.48。公司流动比率为 1.96，当前比率为 2.20，债务股本比率为 6.19。Liquidia 的 12 个月低点为 11.26 美元，12 个月高点为 36.41 美元。公司的 50 日简单移动平均线为 29.46 美元，200 日简单移动平均线为 23.63 美元。</p>
</div><p>Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The business had revenue of $54.34 million for the quarter, compared to analyst estimates of $18.86 million. The business's quarterly revenue was up 1106.7% compared to the same quarter last year. As a group, research analysts predict that Liquidia will post -1.51 earnings per share for the current year.</p>
<div class="lb-trans"><p>Liquidia（纳斯达克代码：LQDA - 获取免费报告）最近在 11 月 3 日发布了季度财报。公司报告每股收益（EPS）为-0.04 美元，超出市场共识预期的-0.45 美元，超出幅度为 0.41 美元。Liquidia 的净利润率为-176.04%，股本回报率为-296.78%。该季度的营业收入为 5434 万美元，而分析师预期为 1886 万美元。与去年同期相比，该季度的营业收入增长了 1106.7%。整体来看，研究分析师预测 Liquidia 在本年度的每股收益将为-1.51 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, insider Rajeev Saggar sold 71,381 shares of the firm's stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $27.00, for a total transaction of $1,927,287.00. Following the transaction, the insider directly owned 176,549 shares in the company, valued at approximately $4,766,823. This trade represents a 28.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Russell Schundler sold 1,072 shares of the business's stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $32.19, for a total value of $34,507.68. Following the completion of the transaction, the general counsel directly owned 577,288 shares in the company, valued at approximately $18,582,900.72. The trade was a 0.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 169,644 shares of company stock worth $4,500,450 over the last 90 days. Company insiders own 26.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Rajeev Saggar 在 11 月 5 日的交易中出售了 71,381 股公司的股票，交易均价为 27.00 美元，总交易额为 1,927,287.00 美元。交易后，该内部人士直接持有 176,549 股公司股票，价值约为 4,766,823 美元。这笔交易代表其持股比例减少了 28.79%。该交易已在 SEC 的法律文件中披露，相关文件可通过此链接访问。此外，公司的总法律顾问 Russell Schundler 在 12 月 1 日的交易中出售了 1,072 股公司的股票，交易均价为 32.19 美元，总价值为 34,507.68 美元。交易完成后，总法律顾问直接持有 577,288 股公司股票，价值约为 18,582,900.72 美元。该交易使其持股比例减少了 0.19%。该销售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士共出售了价值 4,500,450 美元的 169,644 股公司股票。公司内部人士持有公司 26.50% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Liquidia</h2>
<div class="lb-trans"><h2>机构投资者对 Liquidia 的看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the business. Farallon Capital Management LLC increased its position in shares of Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company's stock worth $194,783,000 after acquiring an additional 4,326,876 shares in the last quarter. TCG Crossover Management LLC purchased a new stake in Liquidia during the 3rd quarter worth $38,887,000. Caprock Group LLC purchased a new stake in Liquidia during the 3rd quarter worth $37,114,000. Tyro Capital Management LLC acquired a new stake in Liquidia in the 2nd quarter valued at $15,473,000. Finally, CenterBook Partners LP increased its holdings in Liquidia by 811.7% in the 2nd quarter. CenterBook Partners LP now owns 1,103,850 shares of the company's stock valued at $13,754,000 after purchasing an additional 982,778 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近对该公司的持仓进行了调整。Farallon Capital Management LLC 在第三季度将其在 Liquidia 的持仓增加了 102.1%。Farallon Capital Management LLC 目前持有 8565638 股公司股票，价值 194,783,000 美元，此前在上个季度又增持了 4,326,876 股。TCG Crossover Management LLC 在第三季度购买了 Liquidia 的新股份，价值 38,887,000 美元。Caprock Group LLC 在第三季度购买了 Liquidia 的新股份，价值 37,114,000 美元。Tyro Capital Management LLC 在第二季度收购了 Liquidia 的新股份，价值 15,473,000 美元。最后，CenterBook Partners LP 在第二季度将其在 Liquidia 的持仓增加了 811.7%。CenterBook Partners LP 目前持有 1103850 股公司股票，价值 13,754,000 美元，此前在上个季度又增持了 982,778 股。机构投资者和对冲基金持有公司 64.54% 的股份。</p>
</div><h2>Liquidia Company Profile</h2>
<div class="lb-trans"><h2>Liquidia 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.</p>
<div class="lb-trans"><p>Liquidia Technologies, Inc 是一家临床阶段的生物制药公司，总部位于北卡罗来纳州的研究三角园区。该公司利用其专有的 PRINT®（非湿润模板中的颗粒复制）平台来工程化精确形状和大小的药物颗粒，旨在改善药物的递送、疗效和安全性。通过控制纳米尺度的颗粒特性，Liquidia 旨在增强依赖于靶向递送的呼吸和其他疗法。</p>
</div><p>The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).</p>
<div class="lb-trans"><p>该公司的主要产品候选药物 LIQ861 是一种用于吸入的干粉制剂，适用于患有肺动脉高压（PAH）的患者。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Liquidia</li>
<li>With a $7 Valuation, NNVC Could Disrupt the Biotech Space in 2026</li>
<li>BNZI Posts Record Q3 Revenue – See What’s Driving It.</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>[How To] Claim Your Pre-IPO Stake In SpaceX!</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Liquidia</li>
<li>NNVC 在 2026 年可能会颠覆生物科技领域，估值为 7 美元</li>
<li>BNZI 发布创纪录的第三季度收入 – 看看是什么推动了这一增长。</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>[如何] 认领你在 SpaceX 的 IPO 前股份！</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFFEQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=LQDA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Liquidia Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Liquidia 吗？</h2>
</div><p>Before you consider Liquidia, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Liquidia 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Liquidia 并不在名单上。</p>
</div><p>While Liquidia currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Liquidia 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Liquidia（纳斯达克股票代码：LQDA）被 BTIG Research 给予 “买入” 评级